# Clearside Biomedical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Clearside Biomedical, Inc.). ## Overview Clearside Biomedical, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies delivered into the suprachoroidal space of the eye. Its commercial product, XIPERE, is licensed to partners in the U.S., Canada and parts of Asia-Pacific, while the company’s internal development efforts are centered on CLS-AX and other eye-disease candidates using its SCS Microinjector platform. ## Products & services • XIPERE® (triamcinolone acetonide injectable suspension) • SCS Microinjector platform and kits • CLS-AX ophthalmic drug candidate • Suprachoroidal delivery licensing and collaboration rights - **Commercial ophthalmic product** (20%) — XIPERE is the company’s approved therapy delivered into the suprachoroidal space for eye disease. - **Drug delivery platform** (25%) — The SCS Microinjector platform enables targeted suprachoroidal administration of ophthalmic therapies. - **License and collaboration revenue** (45%) — Upfront, milestone and royalty-based payments from partners using the platform or product rights. - **Development pipeline** (10%) — CLS-AX and other proprietary ophthalmic candidates under preclinical and clinical development. - XIPERE® for suprachoroidal treatment of uveitic macular edema - SCS Microinjector kits sold to licensees for approved products - CLS-AX, a development-stage ophthalmic therapeutic - Suprachoroidal delivery technology licensing and partner access - Collaborations for eye-disease product candidates using the platform ## Customers Clearside sells primarily to pharmaceutical and ophthalmology partners rather than to end patients directly. Its commercial model depends on licensing XIPERE and the SCS Microinjector to companies that can market and distribute in specific territories, while also pursuing collaborations for new eye-disease candidates. The company’s direct customer base is therefore a mix of licensees, collaborators and, to a limited extent, approved-product purchasers of Microinjector kits. - **Commercial licensees** (primary) — Partners such as Bausch + Lomb and Arctic Vision that commercialize XIPERE in licensed territories. - **Development collaborators** (primary) — Pharma and biotech companies that pay for access to the SCS Microinjector and related know-how. - **Approved-product distributors** (secondary) — Licensees that buy SCS Microinjector kits for use with approved ophthalmic products. - **Future pipeline partners** (emerging) — Potential partners for CLS-AX and other candidates if Clearside chooses to out-license development or commercialization. - Pharma partners licensing XIPERE commercialization rights in specific territories - Ophthalmology companies evaluating suprachoroidal delivery for their assets - Licensees purchasing SCS Microinjector kits for approved products - Collaborators funding development through upfronts, milestones and royalties - Potential future partners for CLS-AX and other pipeline assets ## Geography Clearside is headquartered in the United States and its commercial footprint is shaped by partner territories rather than a broad direct-sales network. XIPERE commercialization rights are licensed in the United States and Canada to Bausch + Lomb and in Asia-Pacific, excluding Japan, to Arctic Vision, with Health Canada approval received in July 2025. As a result, geographic exposure is concentrated in North America and selected Asia-Pacific markets, while development, regulatory and financing activities remain U.S.-centered. - **United States** (100%) — Headquarters, development, financing and primary commercial rights are U.S.-centered. - **Canada** (0%) — Commercial rights for XIPERE are licensed to Bausch + Lomb. - **Asia-Pacific (excluding Japan)** (0%) — Commercial rights are licensed to Arctic Vision. - United States is the operating and financing center - Canada is a licensed commercialization market for XIPERE - Asia-Pacific, excluding Japan, is licensed to Arctic Vision - Health Canada approval expands the Canadian market opportunity - Geography is partner-driven, not direct-sales driven ## Strategy Clearside’s near-term strategy is to preserve cash while advancing CLS-AX and other proprietary ophthalmic candidates through development and regulatory milestones. At the same time, it is trying to expand the platform through additional licensing and collaboration agreements that can generate upfront, milestone and royalty revenue without requiring a large commercial infrastructure. The company is also evaluating strategic alternatives and financing options because its current cash runway is limited. - **Complete CLS-AX development** (short-term) — The company needs a successful late-stage asset to create future product revenue and reduce dependence on licensing income. - **Expand platform partnerships** (medium-term) — Additional collaborations can generate non-dilutive cash and validate the SCS Microinjector in more indications. - **Secure financing and strategic flexibility** (short-term) — The company has a limited cash runway and needs capital to continue development and avoid forced restructuring. - Advance CLS-AX toward regulatory approval - Use the SCS Microinjector in partner programs to broaden adoption - Pursue new licenses and collaborations for eye-disease candidates - Monetize royalties and milestone streams from XIPERE - Raise additional capital or pursue strategic alternatives to fund operations ## Risks Clearside faces substantial going-concern and financing risk because it has recurring losses, negative operating cash flow and limited cash runway. Its business also depends on partner execution, regulatory outcomes and the ability to convert its platform into approved products and royalty streams, while any failure to complete a strategic alternative could lead to wind-down or liquidation. - **Going-concern and financing shortfall** [critical] — The company expects to need additional capital to fund operations and complete CLS-AX development. - **Clinical and regulatory failure for CLS-AX** [high] — Pipeline value depends on successful development and approval of the lead candidate. - **Partner and licensing concentration** [high] — Revenue has historically come mainly from license agreements and collaboration payments. - **Strategic alternative / liquidation risk** [critical] — Management disclosed that failure to complete a strategic alternative could lead to bankruptcy, wind-down or dissolution. - **Nasdaq delisting risk** [medium] — Non-compliance with listing requirements could reduce liquidity and investor access. - Limited cash runway may force dilution or operational cuts - Clinical and regulatory risk is concentrated in CLS-AX - Partner dependence can delay or reduce milestone and royalty income - Strategic alternatives may fail, leading to wind-down or liquidation - Nasdaq listing compliance risk could hurt liquidity and valuation ## Accounting Clearside’s reported results are driven by judgment-heavy accounting around license revenue, royalty financing obligations and warrant liabilities. Because much of its revenue comes from upfront, milestone and collaboration arrangements rather than product sales, the timing of revenue recognition can be uneven and highly dependent on contract milestones and performance obligations. The company also relies on estimates for clinical trial accruals, royalty financing interest and fair-value measurements, which can materially affect quarterly results. - **License and collaboration revenue recognition** — Can create lumpy quarterly revenue and non-cash revenue recognition - **Royalty financing obligation** — Affects interest expense and carrying value of the financing liability - **Warrant fair value accounting** — Can cause non-operating income statement volatility - **Clinical trial accruals and R&D estimates** — Can move research expense and operating loss timing - License and collaboration revenue depends on milestone timing and performance obligations - XIPERE partner payments may be recorded as non-cash revenue until obligations are met - Royalty financing liability requires imputed interest and amortization estimates - Warrant liabilities are remeasured at fair value and can create volatility - Clinical trial accruals and R&D estimates affect expense timing --- *Last updated: 2026-04-28T19:58:13.993725+00:00*